secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000318154-25-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)
--------------------------------------------------------------------------------

- Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.
- GAAP EPS $2.65 vs $1.38 (+92%); GAAP operating income $2.7B, margin 30.3%.
- Non-GAAP EPS $6.02 vs $4.97 (+21%); non-GAAP operating margin 48.9%.
- Free cash flow $1.9B in Q2, down from $2.2B, reflecting deferred 2024 tax payments and higher capex.
- Fifteen products had double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, TAVNEOS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/0000318154-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000318154-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer